Pasithea Therapeutics Corp. (KTTA) 8-K Summary
Date of Report: November 4, 2025
Pasithea Therapeutics announced a material clinical update via Item 8.01:
- PAS-004 Clinical Progress: The company activated a new U.S. clinical trial site at the University of Alabama at Birmingham (UAB) for its Phase 1/1b open-label study evaluating PAS-004 in adult patients with neurofibromatosis type 1 (NF1).
- Enrollment is expected to begin immediately at the UAB site.
- The company will serve as the Platinum Sponsor of the 2025 NF Caregivers Symposium hosted at UAB on Nov